908 Devices to Report First Quarter Financial Results on May 13, 2021 and Host 2021 Annual Meeting of Stockholders on June 17, 2021

BOSTON, April 14, 2021 (GLOBE NEWSWIRE) — 908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2021 before market open on Thursday, May 13, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.

The Company also announced that its Annual Meeting of Stockholders will be held on Thursday, June 17, 2021. Due to the continuing COVID-19 pandemic, the meeting will be held online in a virtual-only format and will begin at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. While stockholders will be able to attend the meeting online through a live audio webcast, there will not be a physical location for the annual meeting.

The meeting will focus on stockholder voting on formal business and proxy proposals. Stockholders may vote their shares electronically, online, by mail or by phone prior to the formal business meeting on June 17, 2021. Stockholders entitled to vote at the meeting may also vote their shares online during the meeting.

The record date for stockholders entitled to vote at the virtual meeting is Friday, April 23, 2021. The Company’s proxy statement to be filed will include details confirming how shares may be voted before or during the meeting on June 17, 2021, as well as how to access the meeting as a stockholder.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning. 

Investor Contact

Carrie Mendivil
[email protected]



Inari Medical Announces Global Partnership with Aidoc to Advance the Timely Detection and Treatment of Pulmonary Embolism

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced a new global partnership with Aidoc, the leading provider of enterprise artificial intelligence (“AI”) solutions, to accelerate the adoption and the clinical impact of AI to advance the timely detection and treatment of pulmonary embolism (“PE”).

“The partnership between Inari and Aidoc is a natural fit,” said Dr. Jonathan Paul, Associate Professor of Medicine and Director of the PE program at the University of Chicago Medical Center. “FlowTriever has become a frontline treatment option for intermediate and high-risk PE at our institution. We were proud to pilot and help refine the Aidoc PE suite and have integrated the commercial version of the software into our workflow. We have been pleased to see the impact Aidoc has had on quickly flagging studies with suspected PE findings and improving our patient outcomes.”

“We are the first company to offer an AI-based activation solution that facilitates rapid triage of patient scans with suspected positive findings for PE. Our Care Coordination suite includes Aidoc’s FDA-cleared solution for triage and notification of suspected PE together with Imbio’s FDA-cleared automated RV/LV analysis. The care team involved in the reading workflow can now harness our mobile app at their fingertips to synchronize on the patient treatment path, with access to real-time image, data, video and chat features,” said Elad Walach, co-founder and CEO of Aidoc. “We are extremely excited to be partnering with Inari and see the potential of this partnership to shift the standard of care in PE patient triage and treatment to advance a field that is ripe for innovation.”

“We are committed to helping hospitals develop best-in-class clinical pathways to identify, triage, and treat patients with venous thromboembolism. Recent data has shown that in even the most sophisticated academic programs with established PE Response Teams (“PERT”), as many as three quarters of intermediate-high risk PE patients are still slipping through the cracks and not benefiting from a PERT activation,” said Bill Hoffman, Inari’s Chief Executive Officer. “We believe that artificial intelligence offers a promising new tool to prevent this from happening, and to ensure that all intermediate-high risk PE patients are identified and assessed for optimal treatment as quickly as possible.”

Dr. Thomas Tu, Inari’s Chief Medical Officer, will be hosting a special live Clot Warrior Academy episode on Wednesday, April 21st, at 4pm ET featuring special guests Dr. Hamid Mojibian, Dr. Jonathan Paul, and Dr. Robert Lookstein entitled, Using AI to Optimize PE Patient Triage: The Aidoc Experience. Register here.

About Inari Medical, Inc.

Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.

About Aidoc

Aidoc is the leading provider of artificial intelligence solutions that support physician workflows by helping them expedite patient treatment and improve quality of care. The company’s AI solutions reduce turnaround time and increase quality and efficiency by flagging acute anomalies in real time. These acute anomalies include (but are not limited to) ICH, LVO, PE, C-spine fractures, incidental PE and intraabdominal free air – all of which are commercially in use and FDA cleared. The company offers the broadest integration into the clinical workflow, providing care collaboration tools for radiology as well as multidisciplinary teams including Stroke and PE response teams. Aidoc’s “Always-on” AI acts as a safety net running behind the scenes and can cut the time from scan to diagnosis for some patients from hours to under five minutes, speeding up treatment and improving prognosis. Aidoc’s solutions are currently deployed at over 500 leading medical centers in the U.S. and worldwide. Connect with us at @aidocmed.

Investor Contacts:

Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
[email protected]

Aidoc Medical
Ariella Shoham
[email protected]



CyGlass Makes the Case for SaaS Network Detection and Response

LITTLETON, Mass., April 14, 2021 (GLOBE NEWSWIRE) — CyGlass makes the case for a renewed focus on Network Detection and Response (NDR) as a foundational defensive component to stop ransomware and other targeted attacks in its new whitepaper titled “NDR SaaS: What it Can Do for You.” The paper contends that network defense technology deployed through software-as-a-service – known as NDaaS – can empower resource constrained mid-market enterprises and the service providers that support them to efficiently reduce cybersecurity risk.

Covering four SaaS network defense use cases, including network visibility, standards and regulatory compliance, threat detection, and automation for modern malware defense, the paper is available for download: https://hubs.li/H0K-nJC0

CyGlass’ paper defines the importance of cloud-native, SaaS network defense as critical to organizations with smaller security and IT teams. Many are unable to invest in a SIEM or expensive Security Operations Center but need to protect their on-premise and hybrid cloud networks.

CyGlass is providing associated decision support content, including a new ebook: “Network Defense, Your Secret Weapon to Defeating the Bad Guys.”

The resources are ideal for IT and cybersecurity professionals, who typically manage firewalls, VPNs, and endpoints, but may be unable to protect their networks due to cost and operational constraints of traditional Network Detection and Response (NDR) tools. Additionally, many managed service providers are broadening their cybersecurity solutions to include NDaaS to help their customers cut security costs, reduce resource overhead, and ensure that their cyber-threat mitigation measures are future-proofed.

Download the ebook, whitepaper and read our blog post: “6 Reasons to Make Network Security Central in 2021.”

“Gaining entrance to the network is the adversary’s number one attack priority,” said Ed Jackowiak, President of CyGlass. “By broadening detection to include the network and utilizing Network Defense as-a-Service (NDaaS), security teams have a new, affordable advanced threat detection capability. Lean teams across all industries can defeat sophisticated cyberattacks like ransomware and maintain regulatory compliance at the same time.”

AI driven, SaaS-based network defense has emerged as one of the most cost-effective ways for mid-sized enterprises to identify devices on their network, detect rogue and unprotected devices, identify threats to OT and IoT devices, surface early indicators for ransomware, data theft, and other targeted attacks. This can be accomplished while supporting efforts to improve regulatory compliance across industries such as manufacturing, healthcare, community banks, credit unions, higher education, and local and state governments.

The advantages of a SaaS delivered solution network defense are significant, for example:

  • SaaS network defense does not require the deployment of software, appliances or agents, but taps firewalls, VPNs, and user directories to correlate data.
  • AI-based detection automatically sorts through billions of network conversations and alerts to potential attacks, offering investigation and remediation steps to quickly contain infected systems and prevent further spread.
  • Smaller IT security teams enjoy lower total cost of ownership since solution upgrades, new features and capabilities are included in the cloud service.

Read:


“NDR SaaS: What it Can Do for You”


“Network Defense, Your Secret Weapon to Defeating the Bad Guys”


Blog: “6 Reasons to Make Network Security Central in 2021”


Set up a meeting
with CyGlass to learn more.

ABOUT CYGLASS


CyGlass
is a leading provider of network-centric, threat detection solutions that allow mid-market customers to uncover, pinpoint, and respond to advanced cyber threats that have evaded traditional security controls. CyGlass’ mission is to provide organizations with a new level of intelligence to defend against the most sophisticated cyber-attacks. Its asset oriented, risk-based approach to threat detection and mitigation focuses attention on the emerging attacks which pose the greatest risk. www.cyglass.com. CyGlass is a subsidiary of Nominet UK.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/193e8317-6621-4652-b1b7-de956603e30f



Contact:
Betsy Kosheff
[email protected]
413-717-1410

EHang Holdings Limited Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses of over $100,000 are encouraged to contact the firm before April 19, 2021; click


here


to submit trade information

LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of EHang Holdings Limited (NASDAQ: EH) investors that acquired shares between February 12, 2019 and February 16, 2021. Investors have until April 19, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that during the class period, EHang touted the viability of its aerial vehicle technology, as well as its proliferation into China, North America, and Europe, and its financial success in several detailed press releases. However, EHang failed to disclose to investors that: (i) EHang’s purported regulatory approvals in North America and Europe were for use of its product as a drone, as opposed to carrying passengers; (ii) EHang’s relationship with its purported primary customer is inaccurate; (iii) EHang only collected a fraction of its purported sales since its stock began trading on the NASDAQ; and (iv) EHang’s manufacturing facilities were practically empty, lacking evidence of employees or advanced manufacturing equipment.

Citing “extensive evidence,” analyst Wolfpack Research reported on February 16, 2021 that Ehang is “an elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd.] who appears to us to be more interested in helping inflate the value of its investment in EH … than about buying its products.” It was also reported by Wolfpack Research that EHang “obtained Chinese court records which show that EH’s ADRs may already be in serious jeopardy due to legal issues in China.” EHang’s share price fell $77.79, over 62%, on this news, to close at $46.30 per share, injuring investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 19, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising



Catchpoint Wins 2021 Silver Stevie® Award for Customer Service Four Years in a Row

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) — Catchpoint, the leader in Digital Experience Monitoring (DEM), was presented with a silver Stevie® Award in the 15th annual Stevie Awards for Sales & Customer Service. As the world’s premier business awards, the Stevie Awards recognize the achievements and contributions of organizations and professionals across the globe. This is the fourth consecutive year that Catchpoint has won the Customer Service Department of the Year category.

The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development and sales professionals. The Stevie Awards organizes eight of the world’s leading business awards programs, also including the prestigious American Business Awards® and International Business Awards®.

Winners were recognized during a virtual awards ceremony on April 14.

Building on its award-winning performance from last year, Catchpoint’s support organization focused on delivering the highest quality of service to all its clients with exception transparency and integrity. “Catchpoint was founded on the principle of taking care of its customers first and foremost,” says Mehdi Daoudi, Chief Executive Officer. “Their success is key to our success. Maniacal focus on our clients’ delivery of successful business outcomes is core to what we do every day.”

During the past year, Catchpoint support worked on optimizing cross-departmental data flows which helped to preempt client problems. Improving cross-functional processes allowed support to expand their overall know-how, especially regarding newer products, like WebPageTest and Endpoint monitoring. Additionally, more emphasis was placed on attaining regular tactical customer feedback through in-portal surveys, which helped to assess and verify that customers were receiving the help and support they needed.

Furthermore, a much richer data ecosystem was developed, leveraging data sources beyond traditional ticketing systems, including data from CRM, Marketing Automation and Website Analytics. This diverse data ecosystem presented a more accurate picture of the overall customer satisfaction. It incorporated extensive customer feedback loops, further enriching the quality of the data. These steps created a more proactive support model, moving from simply responding to tickets to proactive customer engagement, thus improving Catchpoint’s support time-to-resolution.

“At Arc XP, we’ve partnered with the best technology in the industry and that includes Catchpoint. Our partnership gives our customers access to additional tools to monitor and improve their overall user experience,” said Scot Gillespie, CTO and GM of Arc XP. “Because Catchpoint simplifies the most complex performance, availability, and monitoring metrics and diagnostics, we’re in turn able to focus our time where it matters for our business and our customers.”

Details about the Stevie Awards for Sales & Customer Service and the list of Stevie winners in all categories are available at www.StevieAwards.com/Sales.

Connect with Catchpoint

Twitter:
@Catchpoint

LinkedIn:
https://www.linkedin.com/company/catchpoint/

About Catchpoint

Catchpoint, the global leader in Digital Experience Monitoring (DEM), empowers business and IT leaders to protect and advance the experience of their customers and employees. In a digital economy, enabled by cloud, SaaS and IoT, applications and users are everywhere. Catchpoint offers the largest and most geographically distributed monitoring network in the industry – it’s the only DEM platform that can scale and support today’s customer and employee location diversity and application distribution. It helps enterprises proactively detect, identify and validate user and application reachability, availability, performance and reliability, across an increasingly complex digital delivery chain. Industry leaders like Google, L’Oréal, Verizon, Oracle, LinkedIn, Honeywell, and Priceline trust Catchpoint’s out-of-the box monitoring platform, to proactively detect, repair, and optimize customer and employee experiences. Learn more at www.catchpoint.com

About The Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Press Contact:

Holly Hagerman
Connect Marketing
801.373.7888
[email protected]
[email protected] 



American Shared Hospital Services Announces Virtual-Only Annual Shareholder Meeting to be Held on June 25, 2021

SAN FRANCISCO, CA, April 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that its Annual Meeting of Shareholders will be held on Friday, June 25, 2021, at 8:00 a.m. PST. The Annual Meeting will be a virtual‑only meeting due to the public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s shareholders and other meeting participants. The Board of Directors has fixed the close of business on April 26, 2021 as the record date for determination of shareholders entitled to notice of and to vote at the Annual Meeting.

About American Shared Hospital Services (NYSE American: AMS)

American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems. For more information, please visit: www.ashs.com.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and MR/LINAC businesses, the risks of the COVID-19 pandemic and its effect on the Company’s business operations and financial condition, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 26, 2020.

Contacts:

American Shared Hospital Services
Ray Stachowiak
Chief Executive Officer
[email protected]

Investor Relations
PCG Advisory
Stephanie Prince
P: (646) 863-6341
[email protected]



Jianpu Technology, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before April 19, 2021; click


here


to submit trade information

LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Jianpu Technology, Inc. (NYSE: JT) investors that acquired shares between May 29, 2018 and February 16, 2021. Investors have until April 19, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that Jianpu made materially misleading and/or false statements, and failed to disclose to investors that: (i) certain transactions carried out by Jianpu’s Credit Card Recommendation Business Unit involved undisclosed relationships or lacked business substance; (ii) that, as a result, Jianpu’s revenue, and expenses for fiscal years 2018 and 2019 were overstated; (iii) that there were material weaknesses in Jianpu’s internal control over financial reporting; (iv) that, as a result, Jianpu’s fiscal year 2018 Form 20-F was reasonably likely to be restated; and (v) that, as a result, Jianpu’s positive statements about the their prospects, operations, and business, were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 19, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising



A ONE-YEAR REFLECTION: USING THE ART OF MEDICINE TO HEAL AMIDST A PANDEMIC

Nationally renowned artists Laura Kimpton, Jeff Schomberg and Anicia Beckwith create art to heal the sick, mend the broken and brighten even the darkest days for hospital patients; Anicia Beckwith debuts a full gallery of fine artistic images of the faces of COVID-19.

Reno, Nev., April 14, 2021 (GLOBE NEWSWIRE) — For leaders, employees and patients of Renown Health, April 14, 2020 will eternally be etched into the COVID-19 pandemic timeline. This was the day the organization invited community leaders and members of the media to tour the Alternate Care Site (ACS) in the Mill St. Parking structure. While other healthcare systems around the world were setting up field hospitals to care for an anticipated influx of COVID-19 patients, Renown was the first to do so in a parking garage.  

During this preview event, Renown Health CEO and President, Dr. Tony Slonim, spoke to area leaders on the decision to commission the $11 million Alternate Care Site, which at the time, was a precautionary measure and a demonstration of Renown’s commitment to the health and well-being of the one million people and communities it serves across 100,000 square miles of Nevada, Lake Tahoe and northeast California.

Also on April 14, 2020, Dr. Slonim observed his 56th birthday. Rather than a celebration to mark the occasion, during the news conference, he received a call that would further alter his life. The intensivist caring for his dad, Anthony Slonim Sr., in a New Jersey hospital, told him that after a hard-fought battle against the novel coronavirus, his father had died.  

Dr. Slonim said, “April 14, 2020 was the day the COVID-19 pandemic was no longer just a tragedy devastating the east coast and other hotspots around the world. COVID-19 hit home, stealing my father and threating both of my beloved communities- New Jersey and Reno – that my family calls home.”

The bright light of LOVE shines through the darkness

Later that week, on April 16, 2020, Beth Macmillan, Executive Director of Artown loaned Renown the LOVE sculpture, a one-ton, welded aluminum artwork with letters 10-feet tall and eight-feet wide created by artist Laura Kimpton and fabricated by Jeff Schomberg, where it lights up Renown Regional Medical Center’s main entrance. LOVE glows, and continues to glow, in Renown’s signature purple every evening, shining brightly for patients, employees, visitors and passersby to enjoy. The art piece debuted at Burning Man in 2019, and was originally slated for the 9/11 Tribute Museum in NYC.  “Healthcare heroes and patients of the hospital have been warmed and inspired by the art and this one word, LOVE! Now, more than ever, the power of art has provided something beautiful on which to focus,” says Beth Macmillan.

In July, the LOVE sculpture found a permanent home at Renown thanks to a donation from the Robert and Dorothy Keyser Foundation. “Through the height of the COVID-19 pandemic, the LOVE sculpture has been a powerful source of hope, inspiration and determination for our community,” said Blake Smith, chair of the Keyser Foundation. “Now, we can’t imagine the entrance of the hospital without it. We are happy that the incredible piece of art will continue shining a bright light while spreading warmth and comfort to all who care for those in our hospitals, patients and families, and those who pass by.” (LOVE sign B-Roll.)

For Dr. Slonim, he found the art a reminder of the love of his father. “I have so much respect for artists like Laura and Jeff, and the way they connect with people through their art. Passing by the LOVE sculpture was immensely therapeutic for me, especially after the loss of my dad,” said Dr. Slonim. “Caring for others and their emotions is also an art. Over the last year, I have been inspired by the compassionate caregivers who have practiced the art of medicine under extremely stressful and difficult conditions brought on by the pandemic.”

When words fail, art speaks

Recognizing art’s powerful healing capabilities, Renown collaborated with prominent artist and fine art photographer, Anicia Beckwith, to immortalize the many battles fought against and amidst COVID-19 within the healthcare system’s walls. Beckwith captured portrait images of Renown caregivers, patients and their loved ones, showing raw and touching scenes from the COVID Intensive Care Unit, Emergency Departments, Neonatal Intensive Care Unit, Wilbur D. May Pediatric Intensive Care Unit and the Alternate Care Site field hospital.

A group of Renown caregivers hold a COVID patient’s hand. Tears well up in their eyes as the patient takes his last breath. Care providers respond to a patient’s only request – a facial shave. The man beams at the sight of his freshly groomed face, and is visibly touched by the tender care he received to make it happen. Lupe, an environmental services worker, takes special care in her efforts to clean and sanitize patient rooms—a craft she has perfected and taken pride in for the 25+ years she’s worked at Renown. These are just a few of the captivating moments Beckwith illustrates through her art.

Beckwith’s full photo gallery of images from Renown are located here; and downloadable visual assets are available here.   

“I was in awe as I watched Renown caregivers administer chest compressions to a patient whose heart had just stopped,” said Beckwith. Promptly after assisting in saving that patient’s life, I observed a nurse walk into the room next door where an elderly patient peacefully discussed coming to the end of hers. I can’t help but wonder how the staff have these conversations daily—always with compassion, dignity and grace. It was an honor and privilege to commemorate this pivotal time in our world’s history, and in turn, aid in the healing process for those hurting both physically and emotionally.” 

“Anicia’s photography provided a comforting outlet for all who were involved in the project,” said Annie Zucker, Manager of Community Impact at Renown. “Her work gave care givers an opportunity to reflect on the last year and fueled the strength and determination they needed to get through it, as sometimes it takes an outside lens to see the magnitude and impact of your work. Anicia gave patients and families an opportunity share their stories and feel support and encouragement from the outside world.”

In addition to taking photos on standard digital cameras, Beckwith also honed her skills using various vintage film cameras and historical techniques.  

“I purposely use these images as testimony to the science in front and behind the lens,” said Beckwith. “COVID has shown us technological advances cannot cure every condition, and sometimes we must go back to the basics to move forward. Some of the film I used for this project is no longer made and rare to possess. Each time I click the shutter translates to one less photographic possibility left in the world. To decide when and what to capture is a metaphor for the importance, reverence and weight I place on the subject in front of me.”

Beckwith plans to continue her photography project at Renown using a 104-year-old camera that was present during the time of the Spanish Flu of 1918. Her goal is to highlight the remarkable stories of strength, resilience and perseverance that have come from the ashes of the pandemic, as we look towards a hopeful future.

“For more than 30 years, art has played an important role at Renown Health,” said Sy Johnson, Chief of Staff at Renown. “Healing is more than getting quality medical care—it’s about the heart, the mind and the spirit. We are proud to bring extraordinary artists like Laura Kimpton, Jeff Schomberg, Anicia Beckwith and others, to find meaningful ways to connect with our patients, employees and community through the universal language of healing arts. Much of the art on our campuses has been made possible by generous artists and donors, who have make a tremendous impact on how our community—and our providers—reflect, engage and heal.” 

If you are interested in supporting the Healing Arts Program at Renown Health, a charitable, non-profit health organization, please consider giving to Renown Health Foundation.  Donations are accepted through the following ways:

  • Make a gift at www.renown.org/give
  • Call Renown Health Foundation at 775-982-5545
  • Mail a check to Renown Health Foundation, 1155 Mill St., O2, Reno, NV 89502
  • Venmo: @RenownFoundation

###

About Renown Health

Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

Attachment



Renown Health Public Relations
Renown Health
775-691-7308
[email protected]

Immunovant, Inc. Technology Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before April 20, 2021; click


here


to submit trade information

​LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Immunovant, Inc. (NASDAQ: IMVT) investors that acquired shares between October 2, 2019 and February 1, 2021. Investors have until April 20, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

On February 2, 2021, Immunovant announced a “voluntary pause of dosing in its ongoing clinical trials for IMVT-1401”. Immunovant admitted that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients” and “out of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in Warm Autoimmune Hemolytic Anemia, in order to inform patients, investigators, and regulators as well as to modify the monitoring program.” Shares of Immunovant fell by more than 42% on the same day, based on this news.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883 
www.portnoylaw.com 

Attorney Advertising



Aqua Metals to Receive Additional $3.4M Insurance Payments

Company Provides Operational Update

MCCARRAN, Nev., April 14, 2021 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), which is reinventing metals recycling with its AquaRefining™ technology, today announced an initial payment towards its business interruption insurance claim. A payment of approximately $1.4 million will be made from the third layer of insurance, completing the total amount due from this insurance layer. An initial $2.0 million is also anticipated to come from the fourth and final insurance layer. This layer has a payment range of up to $25 million. Future insurance proceeds from the business interruption and property claims are anticipated based on current estimates and calculations. The Company has now collected or secured a total of $27.0 million of insurance proceeds related to the November 2019 fire event.

Aqua Metals also confirmed that ongoing discussions with potential licensees and equipment supply partners are advancing. Product development continues with the Company currently operating two Aqualyzers simultaneously. Aqua Metals is also continuing to make progress in research and development related to applying AquaRefining technology to lithium-ion recycling.

“We are pleased with the latest progress payments from our insurance provider and the contribution it makes to a strong financial position that allows us to continue to operate in full on all fronts including business development, R&D, and product development. We are also happy with the commencement of our plant lease-to-buy agreement which allows us to remain in the facility while continuing to operate and fine-tune our AquaRefining technology during a transition phase with the plant’s new occupant,” said Steve Cotton, President and CEO of Aqua Metals. “Further, our discussions with potential AquaRefining technology license partners have continued to progress. We are in advanced discussions with several strong candidates regarding AquaFit retrofits, greenfield builds, direct to oxide applications and will keep the market updated this quarter with new developments.”

About Aqua Metals

Aqua Metals, Inc. (NASDAQ: AQMS) is reinventing metals recycling with its patented hydrometallurgical AquaRefining™ technology. Unlike smelting, AquaRefining is a room temperature, water-based process that emits less pollution. The modular Aqualyzers™ cleanly generates ultra-pure metal one atom at a time, closing the sustainability loop for the rapidly growing energy storage economy. The Company’s offerings include equipment supply, services, and licensing of the AquaRefining technology to recyclers across the globe. Aqua Metals is based in McCarran, Nevada. To learn more, please visit: www.aquametals.com.

Safe Harbor

This press release contains forward-looking statements concerning Aqua Metals, Inc. Forward-looking statements include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes”, “estimates”, “potential” and variations of such words or similar expressions that convey uncertainty of future events or outcomes, or that do not relate to historical matters. The forward-looking statements in this press release include our expectations for the benefits of our new methodology for producing battery manufacturing ready active material and the future of lead acid battery recycling via traditional smelters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the risk that we may not be able to satisfactorily demonstrate to potential licensees the technical and commercial viability of our V1.25 electrolyzer and AquaRefining process; (2) the risk that licensees may refuse or be slow to adopt our AquaRefining process as an alternative to smelting in spite of the perceived benefits of AquaRefining; (3) the risk that we may not realize the expected economic benefits from any licenses we may enter into; (4) the risk that we may not be able to access additional capital as and when needed; and (5) those other risks disclosed in the section “Risk Factors” included in our Annual Report on Form 10-K filed on February 25, 2021 and subsequent SEC filings. Aqua Metals cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Contact: Glen Akselrod, Bristol Capital
(905) 326-1888, Ext. 1
[email protected]